Korsana Biosciences closed a $175 million financing to advance a preclinical Alzheimer’s program built on a platform designed to ferry antibodies across the blood‑brain barrier. The company says its platform improves brain penetration of antibody therapeutics, addressing a major hurdle in neurodegenerative drug development. The raise positions Korsana to accelerate preclinical work and IND enabling studies in a crowded Alzheimer’s landscape where Roche and AbbVie have clinical programs pursuing similar BBB‑penetrant approaches. The funding underscores continued investor appetite for technologies that solve central nervous system delivery. Korsana’s strategy and the round will be watched for translational milestones—PK, target engagement and safety data that will determine whether the platform delivers on its delivery promise.